Journal of Molecular BiologyMolecular BiologyPeer-reviewed journal article
Distinct allosteric networks in CDK4 and CDK6 in the cell cycle and in drug resistance
Wengang ZhangiD, Devin A. Bradburn, Gretchen Heidebrink, Yonglan LiuiD, Hyunbum JangiD, Ruth NussinoviD, Mardo KõivomägiiD
Abstract
Cyclin-dependent kinases 4 and 6 (CDK4 and CDK6) are key regulators of the G1-S phase transition in the cell cycle. In cancer cells, CDK6 overexpression often outcompetes CDK4 in driving cell cycle progression, contributing to resistance against CDK4/6 inhibitors (CDK4/6i). This suggests distinct functional and conformational differences between these two kinases, despite their striking structural and sequence similarities. Understanding the mechanisms that differentiate CDK4 and CDK6 is crucial, as resistance to CDK4/6i--frequently linked to CDK6 overexpression--remains a significant therapeutic challenge. Notably, CDK6 is often upregulated in CDK4/6i-resistant cancers and rapidly proliferating hematopoietic stem cells, underscoring its unique regulatory roles. We hypothesize that their distinct conformational dynamics explain their differences in phosphorylation of retinoblastoma protein, Rb, inhibitor efficacy, and cell cycle control. This leads us to question how their dissimilar conformational dynamics encode their distinct actions. To elucidate their differential activities, molecular mechanisms, and inhibitor binding, we combine biochemical assays and molecular dynamics (MD) simulations. We discover that CDK4 and CDK6 have distinct allosteric networks connecting the {beta}3-C loop and the G-loop. CDK6 exhibits stronger coupling and shorter path lengths between these regions, resulting in higher kinase activity upon cyclin binding and impacting inhibitor specificity. We also discover an unrecognized role of the unstructured CDK6 C-terminus, which allosterically connects and stabilizes the R-spine, facilitating slightly higher activity. Our findings bridge the gap between the structural similarity and functional divergence of CDK4 and CDK6, advancing the understanding of kinase regulation in cancer biology. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=107 SRC="FIGDIR/small/640857v2_ufig1.gif" ALT="Figure 1"> View larger version (33K): org.highwire.dtl.DTLVardef@cbdc16org.highwire.dtl.DTLVardef@1de54deorg.highwire.dtl.DTLVardef@195ed04org.highwire.dtl.DTLVardef@1fbc860_HPS_FORMAT_FIGEXP M_FIG C_FIG
- Citations
- 7
- FWCI
- 2.10
- Field percentile
- top 13%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- The Kinase-Dependent and Independent Functions of Cdk4 and Cdk6 Regulate Continuous Proliferation and the Exit From Quiescence Differently
S. Nataraj, S. W. Blain·bioRxiv·Apr 23, 2020
- Cyclin D-Cdk4,6 drives cell cycle progression via the retinoblastoma protein’s C-terminal helix
B. R. Topacio, E. Zatulovskiy, … J. M. Skotheim·bioRxiv·Aug 21, 2018
- Cell cycle progression mechanisms: slower cyclin-D/CDK4 activation and faster cyclin-E/CDK2
Wengang Zhang, Yonglan Liu, … Ruth Nussinov·bioRxiv·Aug 16, 2023
- The non-kinase function of CDK6 is a key driver of acquired resistance to CDK4/6 inhibitors in Estrogen Receptor-positive breast cancer
S. M. Nashir Udden, Baishan Jiang, … Prasanna G. Alluri·bioRxiv·Nov 11, 2025
- Multi-omics profiling establishes the polypharmacology of FDA Approved CDK4/6 inhibitors and the potential for differential clinical activity
M. Hafner, C. E. Mills, … P. Sorger·bioRxiv·Mar 19, 2019
- Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases
C. Zhang, S. R. Stockwell, … S. Mittnacht·bioRxiv·Apr 8, 2019